People with HIV and hepatitis B virus (HBV)
co-infection, who substituted tenofovir (Viread) for zidovudine (Retrovir)
or abacavir (Ziagen) in their
antiretroviral regimen, saw a reduction in hepatitis B viral load despite HBV being
resistant to lamivudine (Epivir),
according to a poster presented at the 52nd Interscience Conference on
Antimicrobial Agents and Chemotherapy (ICAAC) last week in San Francisco.
Some antiretroviral drugs, including tenofovir
and lamivudine, are also active against hepatitis B virus. European and
US treatment
guidelines recommend that people with HIV/HBV co-infection should
include at least one of these drugs in their antiretroviral regimen.
Hepatitis B virus rapidly develops resistance
to lamivudine, however, which may compromise its effectiveness.
Read more...
No comments:
Post a Comment